Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines

Pharmacogenomics
Daniel L HertzJames M Rae

Abstract

Validation of associations for SNPs in RAC2, NCF4 and SLC28A3, identification of a novel association with a TOP2B SNP and screening 23 SNPs putatively relevant to anthracycline-induced cardiotoxicity. A total of 166 breast cancer patients treated with doxorubicin underwent echocardiogram, including 19 cases with systolic dysfunction (ejection fraction <55%) and 147 controls. Four high priority SNPs were tested in the primary analysis, with appropriate statistical correction, and 23 additional SNPs were screened in an uncorrected secondary analysis. Previously reported associations for RAC2, NCF4 and SLC28A3 could not be validated and a novel association with TOP2B was not discovered in this cohort (all p > 0.05), likely due to inadequate power. Two SNPs were identified in the uncorrected secondary analysis including a protective SNP in ABCB1 (3435C>T, p = 0.049) and a risk allele in CBR3 (V244M, p = 0.012). The associations reported in prior publications and those discovered in this secondary analysis require further replication in independent cohorts.

References

Jan 3, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M ZambettiL Gianni
Sep 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezAllan S Jaffe
Apr 6, 2005·Journal of the American College of Cardiology·Leong L NgIain B Squire
Oct 28, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P FumoleauUNKNOWN French Adjuvant Study Group
Sep 8, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Gisela KerstingLeszek Wojnowski
Dec 23, 2006·Science·Chava Kimchi-SarfatyMichael M Gottesman
Jan 30, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patricia A GanzKathy S Albain
Jun 14, 2008·Pharmacogenetics and Genomics·Lu FanSoo-Chin Lee
May 8, 2009·The Pharmacogenomics Journal·J M RaeUNKNOWN COBRA investigators
Dec 17, 2009·The Journal of Pharmacology and Experimental Therapeutics·Onkar S BainsK Wayne Riggs
Mar 5, 2011·The American Journal of Cardiology·Heloisa SawayaMarielle Scherrer-Crosbie
Sep 9, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henk VisscherUNKNOWN Canadian Pharmacogenomics Network for Drug Safety Consortium
Nov 30, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Javier G BlancoSmita Bhatia
May 23, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sharon H GiordanoJames S Goodwin
Oct 30, 2012·Nature Medicine·Sui ZhangEdward T H Yeh
May 17, 2013·Journal of Human Genetics·Daniel L Hertz, Howard L McLeod
May 17, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel L Hertz, Howard L McLeod
Aug 30, 2014·Journal of the American College of Cardiology·Pimprapa Vejpongsa, Edward T H Yeh
Oct 8, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric J ChowYutaka Yasui
Jun 8, 2015·Breast Cancer Research and Treatment·Megan E V CaramJennifer J Griggs
Aug 4, 2015·Nature Genetics·Folefac AminkengUNKNOWN Canadian Pharmacogenomics Network for Drug Safety Consortium

❮ Previous
Next ❯

Citations

Jun 9, 2016·Pharmacogenomics·Judit C SágiÁgnes F Semsei
Sep 10, 2016·Pharmacology & Therapeutics·Tarek MagdyPaul W Burridge
May 10, 2017·The Pharmacogenomics Journal·J E Megías-VericatS F Aliño
Jul 12, 2018·Pharmacogenomics·Kevin M HuangAlex Sparreboom
Aug 2, 2017·Pharmacogenetics and Genomics·Daniel J SerieNadine Norton
Dec 12, 2017·Congenital Heart Disease·Robert W LoarRicardo H Pignatelli
May 11, 2019·Current Treatment Options in Oncology·Katherine Lee Chuy, Anthony F Yu
Sep 16, 2017·Breast Cancer Research and Treatment·Sara Ruiz-PintoAnna González-Neira
May 2, 2018·Current Oncology Reports·Vivian Y Chang, Jessica J Wang
May 1, 2020·Frontiers in Pharmacology·Zeina N Al-MahayriBassam R Ali
Jul 18, 2020·Clinical Science·Keith DadsonFilio Billia
Jan 16, 2021·Pharmacogenomics·Tarek Magdy, Paul W Burridge
Jan 22, 2021·Arteriosclerosis, Thrombosis, and Vascular Biology·Chi Keung Lam, Joseph C Wu
Oct 29, 2020·Oxidative Medicine and Cellular Longevity·Xinyu YangHongcai Shang
Apr 4, 2021·International Journal of Molecular Sciences·Ji HeYan Li
Apr 20, 2021·Clinical Genetics·Amy M BerkmanAndrew P Landstrom
May 29, 2021·Clinical Science·Anna NarezkinaAlice E Zemljic-Harpf
Jul 9, 2021·Basic & Clinical Pharmacology & Toxicology·Muhammad Erfan UddinAlex Sparreboom

❮ Previous
Next ❯

Methods Mentioned

BETA
urine collection
Assay

Software Mentioned

Assay Design Suite
Sequenom
SAS
Sequenom TyperAnalyzer
Assay Design
R

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

Related Papers

Annals of Internal Medicine
H O Klein
Annals of Internal Medicine
L J Steinherz
Türk Kardiyoloji Derneği arşivi : Türk Kardiyoloji Derneğinin yayın organıdır
Ibrahim Ozdoğru
Nature Genetics
Folefac AminkengCanadian Pharmacogenomics Network for Drug Safety Consortium
© 2022 Meta ULC. All rights reserved